S. Demaria and S. Formenti, Role of T lymphocytes in tumor response to radiotherapy, Frontiers in Oncology, vol.2, p.95, 2012.
DOI : 10.3389/fonc.2012.00095

Y. Keisari, I. Hochman, and H. Confino, Activation of local and systemic anti-tumor immune responses by ablation of solid tumors with intratumoral electrochemical or alpha radiation treatments, Cancer Immunology, Immunotherapy, vol.32, issue.Supl. 1, pp.1-9, 2014.
DOI : 10.1007/s00262-013-1462-2

H. Confino, I. Hochman, and M. Efrati, Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors, Cancer Immunology, Immunotherapy, vol.63, issue.2, pp.191-200, 2015.
DOI : 10.1007/s00262-014-1626-8

J. Gorin, J. Menager, and S. Gouard, Antitumor Immunity Induced after ?? Irradiation, Neoplasia, vol.16, issue.4, pp.319-347, 2014.
DOI : 10.1016/j.neo.2014.04.002

URL : http://doi.org/10.1016/j.neo.2014.04.002

M. Obeid, A. Tesniere, and F. Ghiringhelli, Calreticulin exposure dictates the immunogenicity of cancer cell death, Nature Medicine, vol.279, issue.1, pp.54-61, 2007.
DOI : 10.1038/nm1523

URL : https://hal.archives-ouvertes.fr/inserm-00451702

G. Kroemer, L. Galluzzi, and O. Kepp, Immunogenic Cell Death in Cancer Therapy, Annual Review of Immunology, vol.31, issue.1, pp.51-72, 2013.
DOI : 10.1146/annurev-immunol-032712-100008

M. Chakraborty, S. Abrams, and C. Coleman, External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing, Cancer Research, vol.64, issue.12, pp.4328-4365, 2004.
DOI : 10.1158/0008-5472.CAN-04-0073

E. Reits, J. Hodge, and C. Herberts, Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy, The Journal of Experimental Medicine, vol.123, issue.5, pp.1259-71, 2006.
DOI : 10.1126/science.274.5284.94

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212727

C. Garnett, C. Palena, and M. Chakraborty, Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes, Cancer Research, vol.64, issue.21, pp.7985-94, 2004.
DOI : 10.1158/0008-5472.CAN-04-1525

M. Chakraborty, E. Wansley, and J. Carrasquillo, The Use of Chelated Radionuclide (Samarium-153-Ethylenediaminetetramethylenephosphonate) to Modulate Phenotype of Tumor Cells and Enhance T Cell-Mediated Killing, Clinical Cancer Research, vol.14, issue.13, pp.4241-4250, 2008.
DOI : 10.1158/1078-0432.CCR-08-0335

M. Chakraborty, A. Gelbard, and J. Carrasquillo, Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects, Cancer Immunology, Immunotherapy, vol.62, issue.21, pp.1173-83, 2008.
DOI : 10.1007/s00262-008-0449-x

L. Milas, N. Hunter, and H. Withers, Combination of local irradiation with systemic application of anaerobic corynebacteria in therapy of a murine fibrosarcoma, Cancer Res, vol.35, pp.1274-1281, 1975.

S. Demaria, N. Bhardwaj, and W. Mcbride, Combining radiotherapy and immunotherapy: A revived partnership, International Journal of Radiation Oncology*Biology*Physics, vol.63, issue.3, pp.655-66, 2005.
DOI : 10.1016/j.ijrobp.2005.06.032

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1489884

S. Formenti and S. Demaria, Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift, JNCI Journal of the National Cancer Institute, vol.105, issue.4, pp.256-65, 2013.
DOI : 10.1093/jnci/djs629

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576324

M. Chérel, S. Gouard, and J. Gaschet, 213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma, Journal of Nuclear Medicine, vol.54, issue.9, pp.1597-604, 2013.
DOI : 10.2967/jnumed.112.111997

J. Ménager, J. Gorin, and C. Maurel, Combining ??-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction, PLOS ONE, vol.62, issue.Suppl 1, p.130249, 2015.
DOI : 10.1371/journal.pone.0130249.s001

A. Carpentier, Immunoth??rapie des cancers par oligonucl??otides immunostimulants, m??decine/sciences, vol.21, issue.1, pp.73-80, 2005.
DOI : 10.1051/medsci/200521173

URL : http://www.erudit.org/revue/ms/2005/v21/n1/009994ar.pdf

G. Sgouros, J. Roeske, and M. Mcdevitt, MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of ??-Particle Emitters for Targeted Radionuclide Therapy, Journal of Nuclear Medicine, vol.51, issue.2, pp.311-339, 2010.
DOI : 10.2967/jnumed.108.058651

C. Parker, S. Nilsson, and D. Heinrich, Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.369, issue.3, pp.213-236, 2013.
DOI : 10.1056/NEJMoa1213755

L. Santoro, S. Boutaleb, and V. Garambois, Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis, Journal of Nuclear Medicine, vol.50, issue.12, pp.2033-2074, 2009.
DOI : 10.2967/jnumed.109.066993

URL : https://hal.archives-ouvertes.fr/inserm-00442929

A. Kassis and S. Adelstein, Radiobiologic principles in radionuclide therapy, J Nucl Med, vol.46, issue.1, pp.4-12, 2005.

S. Kitson, V. Cuccurullo, and T. Moody, Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer, Current Radiopharmaceuticals, vol.6, issue.2, pp.57-71, 2013.
DOI : 10.2174/1874471011306020001

D. Mulford, D. Scheinberg, and J. Jurcic, The promise of targeted {alpha}-particle therapy, J Nucl Med, vol.46, issue.1, pp.199-204, 2005.

M. Brechbiel, Targeted alpha-therapy: past, present, future ?, Dalton Trans, vol.43, pp.4918-4946, 2007.

A. Morgenstern, F. Bruchertseifer, and C. Apostolidis, Bismuth-213 and Actinium-225 ??? Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes, Current Radiopharmaceuticals, vol.5, issue.3, pp.221-228, 2012.
DOI : 10.2174/1874471011205030221

S. Huclier-markai, C. Alliot, and N. Varmenot, Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics, Current Topics in Medicinal Chemistry, vol.12, issue.23, pp.2642-54, 2012.
DOI : 10.2174/1568026611212230002

J. Pouget, I. Navarro-teulon, and M. Bardiès, Clinical radioimmunotherapy???the role of radiobiology, Nature Reviews Clinical Oncology, vol.33, issue.12, pp.720-754, 2011.
DOI : 10.1038/nrclinonc.2011.160

J. Jurcic, S. Larson, and G. Sgouros, Targeted Alpha-Particle Immunotherapy for Acute Myeloid Leukemia, American Society of Clinical Oncology Educational Book, vol.34, pp.1233-1242, 2002.
DOI : 10.14694/EdBook_AM.2014.34.e126

K. Baidoo, K. Yong, and M. Brechbiel, Molecular Pathways: Targeted ??-Particle Radiation Therapy, Clinical Cancer Research, vol.19, issue.3, pp.530-537, 2013.
DOI : 10.1158/1078-0432.CCR-12-0298

M. Zalutsky, D. Reardon, and G. Akabani, Clinical Experience with ??-Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6, Journal of Nuclear Medicine, vol.49, issue.1, pp.30-38, 2008.
DOI : 10.2967/jnumed.107.046938

T. Rosenblat, M. Mcdevitt, and D. Mulford, Sequential Cytarabine and ??-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia, Clinical Cancer Research, vol.16, issue.21, pp.5303-5314, 2010.
DOI : 10.1158/1078-0432.CCR-10-0382

C. Raja, P. Graham, A. Rizvi, and S. , Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma, Cancer Biology & Therapy, vol.6, issue.6, pp.846-52, 2007.
DOI : 10.4161/cbt.6.6.4089

B. Allen, A. Singla, and S. Rizvi, Analysis of patient survival in a Phase I trial of systemic targeted ??-therapy for metastatic melanoma, Immunotherapy, vol.3, issue.9, pp.1041-50, 2011.
DOI : 10.2217/imt.11.97

H. Andersson, E. Cederkrantz, and T. Bäck, Intraperitoneal ??-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study, Journal of Nuclear Medicine, vol.50, issue.7, pp.1153-60, 2009.
DOI : 10.2967/jnumed.109.062604

D. Cordier, F. Forrer, and F. Bruchertseifer, Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial, European Journal of Nuclear Medicine and Molecular Imaging, vol.19, issue.4, pp.1335-1379, 2010.
DOI : 10.1007/s00259-010-1385-5

S. Kneifel, D. Cordier, and S. Good, Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P, Clinical Cancer Research, vol.12, issue.12, pp.3843-50, 2006.
DOI : 10.1158/1078-0432.CCR-05-2820

J. Bernier, E. Hall, and G. A. Timeline, Timeline: Radiation oncology: a century of achievements, Nature Reviews Cancer, vol.4, issue.9, pp.737-784, 2004.
DOI : 10.1016/0006-2952(86)90566-6

E. Vacchelli, I. Vitale, and E. Tartour, Trial Watch, OncoImmunology, vol.31, issue.9, p.25595, 2013.
DOI : 10.1158/0008-5472.CAN-11-3912

S. Demaria, B. Ng, and M. Devitt, Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated, International Journal of Radiation Oncology*Biology*Physics, vol.58, issue.3, pp.862-70, 2004.
DOI : 10.1016/j.ijrobp.2003.09.012

K. Shiraishi, Y. Ishiwata, and K. Nakagawa, Enhancement of Antitumor Radiation Efficacy and Consistent Induction of the Abscopal Effect in Mice by ECI301, an Active Variant of Macrophage Inflammatory Protein-1??, Clinical Cancer Research, vol.14, issue.4, pp.1159-66, 2008.
DOI : 10.1158/1078-0432.CCR-07-4485